Testosterone replacement therapy can cause gynecomastia, the development of firm or tender breast tissue in men, because a portion of the testosterone you inject or apply gets converted into estradiol, the primary form of estrogen. When that conversion runs ahead of your body's ability to clear the extra estrogen, breast tissue can respond by growing. It's a well-documented but preventable side effect, and in most cases it can be caught early or avoided altogether with the right dose, monitoring, and, when needed, an aromatase-blocking medication.
Why Does TRT Cause Gynecomastia?
Testosterone doesn't stay as testosterone once it enters your bloodstream. An enzyme called aromatase, found in fat tissue, the liver, and elsewhere in the body, converts a portion of circulating testosterone into estradiol. This is a normal process that happens in every man, but on TRT there's simply more testosterone available to convert, which means estradiol levels tend to rise along with it.
Breast tissue in men has estrogen receptors, and when estradiol is elevated relative to testosterone's own tissue-level effects, it can stimulate glandular breast tissue to grow. This is the same basic mechanism behind gynecomastia in other contexts, including puberty and certain medical conditions, where an imbalance between estrogen and androgen activity at the breast tissue level is the underlying driver (Endocrine-Related Cancer, Aromatase and Gynecomastia). On TRT, the imbalance is usually caused by a dose that's pushing estradiol too high, a body composition with more aromatase-rich fat tissue, or a delivery method that creates sharp testosterone peaks that get aromatized in bursts.
How Common Is Gynecomastia on TRT?
It's a recognized but not universal side effect. Case reports and clinical reviews have documented testosterone therapy as a cause of drug-induced gynecomastia for decades, and it's one of the medication classes clinicians are specifically taught to screen for when evaluating new breast tissue growth in men (Gynecomastia: Clinical Evaluation and Management, PMC, 2014). In practice, most men on a well-monitored TRT protocol never develop noticeable gynecomastia, but breast tenderness or early glandular changes are common enough that clinics that manage TRT well ask about it at nearly every follow-up.
Men with higher body fat percentages are generally at greater risk, since fat tissue is where a large share of testosterone-to-estradiol conversion happens. Men on higher doses, older protocols using large infrequent injections, or anyone who has gone without bloodwork for an extended stretch are also more likely to notice symptoms.
What Are the Early Signs?
- Tenderness or soreness directly under the nipple, often the very first sign, sometimes before any visible change
- A small, firm, disc-shaped lump beneath the nipple area, which is glandular tissue rather than fat
- Nipple sensitivity to clothing or touch that wasn't there before starting treatment
- Puffiness or swelling that may be more noticeable on one side than the other initially
Catching these signs early matters, because glandular tissue that has been present for many months becomes harder to reverse with medication alone and may eventually require a surgical consult if it doesn't resolve.
How Is TRT-Related Gynecomastia Prevented and Treated?
- Regular estradiol testing. Checking estradiol alongside total and free testosterone at follow-up labs is the single most effective way to catch a rising trend before it causes symptoms. If you're not sure whether your clinic tests it, ask, since some lower-cost protocols skip it by default.
- Dose adjustment. If estradiol is running high, the most common first step is simply lowering the testosterone dose or spacing injections more evenly to reduce peaks, which lowers the total substrate available for aromatization.
- Aromatase inhibitors. For men whose estradiol stays elevated despite dose changes, providers may add a low dose of an aromatase inhibitor such as anastrozole, which directly blocks the enzyme responsible for the testosterone-to-estradiol conversion. A 2021 review of TRT patients managed with aromatase inhibitor therapy found the medication was commonly used specifically in men with elevated estradiol levels or estrogen-related symptoms, underscoring that this is a targeted response to measured hormone levels rather than a routine add-on for everyone (Punjani et al., PMC, 2021). Aromatase inhibitors carry their own risks when overused, including driving estradiol too low, which can affect bone density, joint comfort, and libido, so dosing needs to be guided by lab values rather than guesswork.
- SERMs for early or mild cases. Selective estrogen receptor modulators can block estrogen's effect directly at breast tissue and are sometimes used for early-stage tenderness rather than adjusting the aromatase pathway itself.
- Body composition. Reducing body fat lowers the amount of aromatase-rich tissue available to convert testosterone into estradiol, which can meaningfully improve the ratio over time independent of any medication change.
None of these steps work well without data. A clinic that adjusts your protocol based on symptoms alone, without checking estradiol, is working with half the picture. If you want a fuller sense of what your lab panel should include, see our guide to managing estrogen on TRT.
